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This research seeks to address the problem of methicillin-resistant Staphylococcus aureus (MRSA) by
discovering synergistic antibacterial natural substances from traditional Chinese herbs using antibacterial
bioassays. Six compounds, including three neolignans ()-acuminatin (1), ()-denudatin B (2), puberulin
D (3), and three benzocyclohexane oxide derivatives ferrudiol (4), ellipeiopsol B (5) and zeylenol (6), were
isolated and puriﬁed by silica gel and reverse-phase silica gel column chromatography, and the chemical
structures were determined through NMR spectroscopy, MS, together with CD and calculated CD
spectroscopic methods. Synergistic activity was determined using strain SA1199B, a strain that
overexpresses the major S. aureus multidrug transporter, NorA. Compounds 1–6 showed synergistic
activity combined with norﬂoxacin against SA1199B, with FICI values of 0.13, 0.25, 0.25, 0.52, 0.08 and
0.27 respectively. The synergistic eﬀects of the benzocyclohexane oxide derivatives with norﬂoxacin
were further demonstrated through strain growth kinetics experiments. In the mechanistic experiment,
the compounds showed signiﬁcant accumulation and/or inhibition eﬀects for EtBr eﬄux in SA1199B.
These active compounds showed no toxicity to HEK293T cells at a concentration of 100 mM in the
cytotoxicity evaluation experiments. Combined with eﬄux pump inhibitors, classic antibiotics that are
substrates for eﬄux pumps may yet play a role in the therapy of drug-resistant bacteria where a lower
dose could result in improved safety.1. Introduction
Over the past few decades, there has been a dramatic decrease
in the number of pharmaceutical companies developing new
antimicrobial drugs.1 Methicillin-resistant Staphylococcus
aureus (MRSA) is still cause for concern due to the small number
of compounds that can be used therapeutically for this
organism and resistance associated with their use.2 A supple-
mental strategy to overcome resistance is to develop agents that
can suppress bacterial resistance mechanisms, and such agents
are known as resistance-modifying agents (RMAs).3 These
compounds may work by synergism, which is dened as
a phenomenon in which two or more diﬀerent compounds are
combined to enhance their individual activity,4 and thisy, Shanghai 201203, China. E-mail:
nd Biological Chemistry, UCL School of
's Aﬀairs Medical Centre and Department
iseases, School of Medicine, Wayne State
tion (ESI) available. See DOI:
5approach is now widely recognized and can be directly applied
to the development of new pharmaceuticals.5
Whilst there are diﬀerent kinds of mechanisms of drug-
resistance, multidrug-resistance (MDR)-related eﬄux is
a common and important one, and has been reported for many
organisms, including bacteria, fungi and protozoa, and also as
a mechanism of resistance in human tumor cells.6 Examples of
eﬄux-related resistance mechanisms that have been reported
for S. aureus include those conferred by QacA and NorA, which
are MDR transporters.7 Fluoroquinolone resistance, facilitated
by the NorA eﬄux protein,6 has been shown to be a particular
risk factor for mortality associated with infections by S. aureus.8
Therefore, in our research, we have studied the eﬀects of plant
natural products on S. aureus strain SA1199B, which is uo-
roquinolone resistant by means of increased NorA production
as well as a critical amino acid substitution within the quino-
lone resistance-determining region of GrlA.9We evaluated the in
vitro synergism of extracts of Piper betle Linn. (Piperaceae) with
the uoroquinolone antimicrobial drug noroxacin against
S. aureus strains by the broth microdilution method.10
P. betle is widely distributed in Yunnan, Guangxi and the
Guangdong province of China,11 and cultivated in India for its
leaves, which are used for chewing.12 Experimentally, the
extracts and herbal material of P. betle have been shown toThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinepossess many kinds of curative properties such as laxative,
aphrodisiac, antimicrobial,13 antioxidant14 and to improve
appetite.15 The plant is rich in phenolics,16 methyl piperbetol,
piperol A and piperol B,17 and some benzocyclohexane oxide
derivatives and neolignans.18 In this report, we studied the
chemical constituents of P. betle, guided by an antibacterial
synergistic assay, and a series of preliminary mechanistic
experiments were carried out.2. Materials and methods
2.1. General experimental instruments and materials
The silica gel (100–400 mesh) used in column chromatography
was purchased fromQingdaoMarine Chemical Plant, China. 1H
and 13C NMR spectra were obtained on a Varian Mercury Plus
400 MHz spectrometer. EI-MS spectra were measured with an
Agilent 5973N MSD mass spectrometer. IR spectra and UV
spectra were recorded on an Avatar 360 ESP FTIR spectropho-
tometer and a HITACHI U-2900 spectropolarimeter, respec-
tively. Fractions obtained from column chromatography were
monitored by thin layer chromatography (TLC) (silica gel plate
HGF254, Yantai Huangwu Chemical Plant, Yantai, China).
Optical density was recorded on a Multiskan FC (Thermo Co.
Ltd, USA), and uorescence was recorded on a Tecan M 1000
plate reader (Tecan Co. Ltd., Switzerland).2.2. Extraction and bioactivity-guided isolation
P. betle was collected in Mengla County, Yunnan Province of
China, in December of 2002, and identied by Professor Xu You-
Kai, Professor of Xishuangbanna Botanic Garden in Yunnan
province, the Chinese Academic of Science. A voucher specimen
(148888) was deposited at the Herbarium and used in identi-
fying the plant by professor You-Kai, and in the same time, we
also saved a plant sample in our lab in School of Pharmacy,
Fudan University. 100 g air dried leaves of P. betle were extracted
using 95% ethanol by maceration and 10.8 g resinous extract
was obtained. The resulting resin was then extracted using
chloroform by solid–liquid extraction and yielded a gum (3 g).
The total chloroform extract, was dissolved in acetone and
mixed with silica gel and then subjected to silica gel and eluted
with a gradient of chloroform–acetone (99 : 1–7 : 3). Fractions
A–H were obtained by TLC monitoring with similar eluents. All
of the eight fractions were subjected to Middle Chromatogram
Isolated (MCI) gel to remove chlorophyll. Under the guidance of
the synergistic activity, some fractions were further separated
selectively and six compounds were obtained. Compound 1,
named ()-acuminatin (8 mg) was isolated from fraction B by
silica gel column chromatography with elution of petroleum
ether–acetone (95 : 5). Compounds 2 and 3, named ()-denu-
datin B (10 mg) and puberulin D (3 mg), were both obtained
from fraction C. Compound 2 was isolated by forward silica gel
column chromatography with elution of petroleum ether–ethyl
acetate (9 : 1) while compound 3 was obtained by high-pressure
liquid chromatography (HPLC) preparation with elution of
methanol–water (8 : 2). Fraction E was further separated to
obtain compound 4, named ferrudiol (12 mg), by silica gelThis journal is © The Royal Society of Chemistry 2016column chromatography with elution of chloroform–acetone
(95 : 5). Compounds 5 and 6, named ellipeiopsol B (20 mg) and
zeylenol (35 mg), were isolated from fraction F by silica gel
column chromatography and Sephadex LH-20 gel column
chromatography. The structures of all the compounds were
deduced from spectroscopic methods (NMR spectroscopy and
mass spectrometry) and all the resulting data were in good
agreement with the literature.
2.3. HPLC ngerprint
The chloroform extract and six compounds (1–6) were dissolved
in methanol, respectively. Each solution (2 mg mL1) was sub-
jected on the HPLC (10 mL, Agilent 1200) using an autosampler
at 25 C. The specications and models of using column are
eclipse XDB-C18, 5 mm, 4.6  250 mm (Agilent). The eluent ow
rate was set to 1.0 mL min1 propelled by an Agilent 1200 series
G1312B SL binary pump, with ultra-pure water and HPLC-grade
methanol (solutions A and B) eluting using the gradient
method: started with 50% B, changing to 70% B within 30 min,
then changing to 90% B within 40 min, the total time was
75 min. UV detector was used and the signal of compounds was
monitored at a wavelength of 254 nm.
2.4. Electronic circular dichroism (ECD) spectral
calculations
The absolute congurations of the six compounds were pre-
dicted by a quantum chemical calculation using Gaussian 09.19
The geometries of all compounds were optimized at the
B3LYP/6-31G level of density functional theory (DFT). The
Electronic Circular Dichroism (ECD) spectra were then calcu-
lated using the time dependent DFT (TDDFT) method at the
B3LYP/6-311++G** level in the solvent methanol.
2.5. Antibacterial minimum inhibitory concentration (MIC)
assay
Five Staphylococcus aureus strains (SA1199B, XU212, RN4220,
EMRSA-15 and EMRSA-16) were used in experiments, all of
which had a drug-resistance phenotype. Strain SA1199B, which
overexpresses the norA gene encoding the NorA MDR eﬄux
pump, was the generous gi of Professor Glenn W. Kaatz.20
Strain XU212, which possesses the TetK tetracycline eﬄux
protein, was provided by Dr Edet Udo.21 Strain RN4220, was
provided by Dr Jon Cove.22 Strains EMRSA-15 and strain
EMRSA-16, which are epidemic methicillin-resistant (MRSA)
strains, were the kind gi of Dr Paul Stapleton.23
Minimum inhibitory concentration (MICs) values were
determined following the guidelines of Clinical Laboratory
Standards Institute.24 Mueller-Hinton broth (MHB; Oxoid), was
used which was supplemented with 20 and 10 mg L1 of Ca2+
and Mg2+ respectively. All bacterial suspensions were adjusted
to 5  105 cfu mL1 for the bioassay. 2% DMSO in broth served
as the negative control and vancomycin (Sigma Chemical Co.
Ltd) served as the positive control. All compounds and chloro-
form extract were dissolved in DMSO respectively and then
diluted with MHB, added into 96-well microtiter plate, with
a concentration of 512 mg L1 in upmost row and eachRSC Adv., 2016, 6, 43518–43525 | 43519
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View Article Onlinefollowing row (B–H) contained half concentration of the
previous one. Both controls and treatments were tested in
duplicate. Aer incubation at 37 C for 24 h, 20 mL of 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT;
Biosharp) solution (5 mg mL1) was added into each well to
determined MIC. MTT colorimetric assay was performed to
determine the MIC values. The minimum concentrations for
colour appearing from black to yellow (completely inhibited the
visible bacterial growth) were recorded as the MIC values
against test strains.2.6. Synergy tests
The ve drug-resistant S. aureus strains described above were
used in broth microdilution antimicrobial checkerboard
assays10,25 to examine for the presence of a synergistic interac-
tion. The rows of a 96-well microtiter plate contained
compounds isolated with a concentration of 128 mg L1 in
upmost row (A) and each following row (B–G) contained half
concentration of the previous one. Row (H) contained no
compounds but MHB. A similar procedure was carried out
along columns (1–12) with concentration of specic antibiotics
ranging from 256 to 0.5 mg L1. All of the treatments were
tested in duplicate wells. MTT colorimetric assay was performed
to determine the MIC values, which were used to evaluate the
eﬀects of the combination of compounds and antibiotics by
calculating the fractional inhibitory concentration index (FICI)
according to the formula:
FICI ¼ MIC ðantibiotic combined with compoundÞ
MIC ðantibiotic aloneÞ
þMIC ðcompound combined with antibioticÞ
MIC ðcompound aloneÞ
“Synergy” eﬀects were dened when the FICI was less than or
equal to 0.5. When the FICI was greater than 0.5 and less than or
equal to 4.0 this was regarded as an “indiﬀerence” eﬀect; whilst
“antagonistic” eﬀects were observed when the FICI was greater
than 4.0.26 An isobologram was constructed to depict the results
of the checkerboard assay and the FICI values.2.7. EtBr eﬄux assay
Those compounds for which an adequate amount existed were
chosen for an eﬄux assay as previously described.27 Test
organisms were grown overnight in cation-adjusted MHB until
the OD620 ¼ 0.4 and then followed by the addition of carbonyl
cyanide m-chlorophenylhydrazone (CCCP, Across Organic) and
EtBr (Sigma) (nal concentrations, 100 mM (20.5 mg L1) and
25 mM (2.725 mg L1), respectively). Aer incubation at room
temperature for 20 min, 4 mL of the inocula was pelleted at
13 000g for 5 min and then re-suspended in 3 mL of fresh MHB
containing CCCP or the tested compounds (nal concentra-
tions, all 100 mM) (35.6 mg L1 for compound 2, 48.8 mg L1 for
compound 4 and 38.4 mg L1 for compound 5 and 6).
Fluorescence of the suspension was monitored continuously
(excitation and emission wavelengths were 530 and 600 nm,43520 | RSC Adv., 2016, 6, 43518–43525respectively; slit width was 5 nm) every ve min for one hour. All
tested compounds and the control were measured in triplicate.2.8. EtBr accumulation assay
Ferrudiol (4), ellipeiopsol B (5) and zeylenol (6) were subjected
to the EtBr accumulation assay by the uorometric method due
to their adequate quantity. This assay was conducted according
to a modication of reported methods.28 Organisms were grown
overnight in cation-adjusted MHB until the OD620 reached 0.4.
Then 3 mL of the inoculum was collected by centrifugation at
13 000g for 5 min and re-suspended using fresh MHB to adjust
the OD620 to 0.4. Culture medium (50 mL) and an equal volume
of CCCP and test compounds (nal concentrations, all 100 mM)
(20.5 mg L1 for CCCP, 48.8 mg L1 for compound 4 and 38.4
mg L1 for compound 5 and 6) were added to a 96-well plate
containing 100 mL of EtBr (nal concentration, 12.5 mM) (1.36
mg L1). The 96-well plate was lled with 200 mL of the
suspension and monitored continuously by the uorescence of
the suspension (excitation and emission wavelengths were 530
and 600 nm, respectively; slit width was 5 nm) every ve min for
one hour. All tested compounds and the control were measured
in triplicate.2.9. Growth curves
Growth kinetics was determined according to Garvey29 with
some modications. The growth kinetics of strain SA1199B in
the absence or presence of the benzocyclohexane oxide deriva-
tives were determined by monitoring the optical density at 620
nm every 2 h at 37 C for 12, 24, 36 and 48 h using a microwell
reader (Multiskan FC, Thermo). The nal concentration of
compounds and noroxacin both alone and in combination
with each other were 128 mg L1 and 4 mg L1. All tested
compounds and the control were measured in triplicate.2.10. Cytotoxicity evaluation
To determine whether the benzocyclohexane oxide derivatives
were toxic, a cytotoxicity assay using a human embryonic kidney
cell line (HEK293T) with the method of the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay was carried out and the cell viability was measured
according to Lu with some modications.30 Cells were plated
into 96-well plates at a cell density of 5  103 cells per well and
allowed to grow in a 5% CO2 incubator. Aer 24 h, the medium
was removed and replaced by fresh medium containing the
tested compounds that were dissolved in DMSO and diluted to
various concentrations (nal concentrations were 100, 30, 10, 3,
1 mM respectively) with complete medium (RPMI 1640 + 10%
FBS) before the experiment, and the nal concentration of
DMSO was 0.1%. Aer 24 hours incubation, cultures were
incubated in 200 mL of medium with 20 mL of 5 mg mL1 MTT
solution for 4 hour at 37 C. The medium with MTT was
removed, and 150 mL of DMSO was added to each well to
dissolve the formazan. The absorbance at 490 nmwasmeasured
with a microwell reader (Multiskan FC, Thermo). The inhibitory
percentage of each compound at various concentrations wasThis journal is © The Royal Society of Chemistry 2016
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View Article Onlinecalculated, and the IC50 value was determined. All tested
compounds and the control were measured in triplicate.
3. Results
3.1. Extraction and isolation
Compounds 1–6 were identied as the known chemical constitu-
ents ()-acuminatin (1),31 ()-denudatin B (2),31 puberulin D (3),32
ferrudiol (4),33–35 ellipeiopsol B (5)34,35 and zeylenol (6)34,35 (Fig. 1) by
comparison of their physical properties and spectral data (ESI
Tables S1 and S2†) with the literature. The chemical systematic
name of the compound 3 is (7S,8S,10R,50R,60S)-D2
0,80-60-acetoxy-30-
methoxy-3,4-methylenedioxy-40-oxo-8.10,7.50-neolignan,32 which
was given a trivial name as puberulin D in this manuscript. The
absolute conguration of compounds 1–6 were determined by
comparison of their circular dispersion (CD) spectra with those
reported and with the quantum chemical calculated CD spectra
(ESI Fig. S1†). The purities of all six compounds were $95% as
determined by HPLC (Fig. S2†).
3.2. HPLC ngerprint
The HPLC ngerprint with well resolved peak separation for the
chloroform extract of P. betle was obtained (Fig. 2). Compounds
1–6 were unambiguously recognized in the ngerprint byFig. 1 Chemical structures of compounds 1–6 isolated from Piper betle
This journal is © The Royal Society of Chemistry 2016comparing with their retention time (Fig. 2). The retention time
of ()-acuminatin (1) was 41.473, which is the peak with
retention time 41.418 in the ngerprint. We can were also able
to identify the peaks for ()-denudatin B (2), puberulin D (3),
ferrudiol (4), ellipeiopsol B (5) and zeylenol (6) in the ngerprint
with a retention time 31.431 min, 29.531 min, 39.988 min,
16.740 min and 11.281 min, respectively. The relative
percentage contents of compounds 1–6 were 6.3%, 9.4%, 4.1%,
10.5%, 9.5% and 11.3% respectively. Total contents of the six
compounds were more than y percent.3.3. Antibacterial minimum inhibitory concentration (MIC)
assay
The chloroform extract and compounds 1–6 were assayed for
antibacterial activity against all test strains of S. aureus, and
none had any signicant antibacterial eﬀect in that all MICs
exceeded 512 mg L1.3.4. Synergy tests
The ve drug-resistant S. aureus strains described above and
antibiotics to which the strains were resistant were employed.
The results showed that compounds 1–6 showed signicant
synergistic eﬀects with noroxacin against strain SA1199B,.
RSC Adv., 2016, 6, 43518–43525 | 43521
Fig. 2 The HPLC ﬁngerprint of chloroform extract.
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View Article Onlinewhich overexpresses the norA gene encoding the NorA MDR
eﬄux pump, but no synergetic eﬀects were observed for the
other four strains (XU212, RN4220, EMRSA-15 and EMRSA-16).
()-Acuminatin (1), ()-denudatin B (2), puberulin D (3), fer-
rudiol (4), ellipeiopsol B (5) and zeylenol (6) reduced the MIC of
noroxacin against SA1199B by eight-, four-, four-, two-, sixteen-
and eight-fold respectively. This resulted in a concentration
decrease of the antibiotic from 64 to 8 mg L1, 128 to 32 mg L1,
64 to 16 mg L1, 64 to 32 mg L1, 64 to 4 mg L1 and 64 to 8 mg
L1, respectively (Table 1). The FICI of the combinations were
0.13, 0.25, 0.25, 0.52, 0.08, 0.27, respectively and we were able to
construct an isobologram depicting the synergistic eﬀects for
the six compounds (ESI Fig. S3†).3.5. EtBr eﬄux assay
All compounds were subjected to an EtBr eﬄux assay by the
uorometric method without ()-acuminatin (1) and puberulin
D (3) due to their limited quantity. As shown in Fig. 3, ferrudiolTable 1 Minimum inhibitory concentrations (MIC) and fractional inhibitio
aureus SA1199Ba
Drug-resistant strain Agent
MIC
Alo
SA1199B
()-Acuminatin (1) >51
Noroxacin 64
()-Denudatin B (2) >51
Noroxacin 128
Puberulin D (3) >51
Noroxacin 64
Ferrudiol (4) >51
Noroxacin 64
Ellipeiopsol B (5) >51
Noroxacin 64
Zeylenol (6) >51
Noroxacin 64
a (1) FICI# 0.5 is dened as synergy; 0.5 < FICI# 1 as additive; 0.5 < FICI#
direct inhibitory eﬀects on ve strains and no synergetic eﬀects combined
table.
43522 | RSC Adv., 2016, 6, 43518–43525(4), ellipeiopsol B (5) and zeylenol (6) had moderate eﬄux pump
inhibitory eﬀects against SA1199B (Fig. 3a, b and d), whereas
()-denudatin B (2) demonstrated a strong eﬄux inhibitory
eﬀect against this strain (Fig. 3c). Within the rst half hour,
ferrudiol (4) showed a similar eﬄux pump inhibitory eﬀect
compared with the positive control CCCP, while a stronger
eﬀect than CCCP over the subsequent half hour was observed
(Fig. 3a). Zeylenol (6) showed a similar activity compared with
CCCP within one hour (Fig. 3b) and ()-denudatin B (2)
exhibited a stronger activity than CCCP within one hour
(Fig. 3c). Ellipeiopsol B (5) showed a stronger activity than
CCCP, but with a weaker eﬀect than CCCP over the second half
hour (Fig. 3d).3.6. EtBr accumulation assay
Ferrudiol (4), ellipeiopsol B (5) and zeylenol (6) exhibited EtBr
accumulation eﬀects with strain SA1199B (Fig. 4). They all
increased the concentrations of EtBr compared with the vehiclen concentration indices (FICI) of six compounds from Piper betle for S.
(mg L1)
FIC FICIne Combination
2 2 <0.004
<0.13
8 0.125
2 2 <0.004
<0.25
32 0.25
2 2 <0.004
<0.25
16 0.25
2 8 <0.02
<0.52
32 0.5
2 8 <0.02
<0.08
4 0.06
2 8 <0.02
<0.27
16 0.25
4 as indiﬀerent; 4 < FICI as antagonistic. (2) All six compounds have no
with the other four strains, so data about those was not listed in above
This journal is © The Royal Society of Chemistry 2016
Fig. 3 EtBr eﬄux inhibitory eﬀects of ferrudiol (4), zeylenol (6), ()-denudatin B (2) and ellipeiopsol B (5) against S. aureus SA1199B.
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View Article Onlinecontrol, especially ellipeiopsol B (5), showing stronger activity
than the positive control CCCP (Fig. 4c). Zeylenol (6) had
a similar activity compared with CCCP (Fig. 4b) and ferrudiol (4)
showed a weaker activity compared to CCCP but with a signi-
cantly stronger eﬀect than the control vehicle (Fig. 4a).3.7. Growth curves
Time-growth experiments of SA1199B in the absence or pres-
ence of noroxacin and compounds alone and in combination
with each other are shown in Fig. 5. The ordinate represents the
increased several times of OD value. The results suggested that
the increase of strain growth in a mixture of noroxacin and
compounds was less than strain growth with noroxacin or
compounds alone. All three of the tested compounds ferrudiol
(4), ellipeiopsol B (5) and zeylenol (6) alone showed weak growth
inhibitory activity within the rst 30 h, while no activity within
the last 18 h was observed. Interestingly, SA1199B with nor-
oxacin and the test compounds exhibited a lower OD value
increase than with SA1199B and noroxacin alone within 48 h
(Fig. 5).3.8. Cytotoxicity evaluation
In terms of the cytotoxic activity of the benzocyclohexane oxide
derivatives, ferrudiol (4), ellipeiopsol B (5) and zeylenol (6) showed
no toxicity with IC50 values within the concentration of 100 mM for
HEK293T cells, a human embryonic kidney cell line. As shown in
the ESI Fig. S5,† within the 1–100 mM L1 (<48.8 mg L1 forThis journal is © The Royal Society of Chemistry 2016compound 4, <38.4 mg L1 for compound 5 and 6) concentration
range of all three compounds the viability of HEK293T was
approximately 100%. The compounds on their own had no cyto-
toxicity and did not increase the toxicity of noroxacin compared
with noroxacin alonewithin the antibacterial eﬀect concentration
(ESI Fig. S6†).4. Discussion
In the primary experiment, the chloroform extract of Piper betle
showed no direct bacterial growth inhibition but had
a marginal synergistic eﬀect together with the antibiotics.
Under the guidance of a synergistic bacterial assay employing
a checkerboard methodology in combination with chromatog-
raphy, three neolignans [()-acuminatin (1), ()-denudatin B (2)
and puberulin D (3)] and three benzocyclohexane oxide deriv-
atives [ferrudiol (4), ellipeiopsol B (5) and zeylenol (6)] were
isolated from the extract. These compounds were isolated from
other Piper species such as P. cubeba, P. puberulum and so on
previously. All six compounds showed no direct bacterial inhi-
bition but had signicant synergistic activity with noroxacin
against strain SA1199B. The MIC values of the antibiotic
combined with the compounds was several times less than that
of the antibiotic alone (Table 1). The six compounds were
known compounds, but there are no reports on their synergistic
activities on drug-resistant strains. Considering the tested
strain SA1199B overexpressing the NorA eﬄux pump, weRSC Adv., 2016, 6, 43518–43525 | 43523
Fig. 4 EtBr accumulation eﬀects of ferrudiol (4), zeylenol (6) and
ellipeiopsol B (5) against S. aureus SA1199B.
Fig. 5 Time-growth of SA1199B in the absence or presence of nor-
ﬂoxacin and benzocyclohexane oxide derivatives.
RSC Advances Paper
Pu
bl
ish
ed
 o
n 
27
 A
pr
il 
20
16
. D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 C
ol
le
ge
 L
on
do
n 
on
 0
3/
03
/2
01
7 
14
:5
5:
27
. 
View Article Onlinepostulated that the synergistic eﬀects were as a result of NorA
inhibition.
All tested compounds showed a similar inhibitory activity on
strain SA1199B compared with the positive control (CCCP) in
the EtBr eﬄux and accumulation assays (Fig. 3 and 4). These
results indicated that eﬄux pump inhibition may contribute to
the synergistic eﬀects of these compounds against SA1199B.
In order to further conrm the synergistic eﬀects, growth
kinetics in the presence and absence of compounds were
determined. The synergistic eﬀects were obvious since the OD43524 | RSC Adv., 2016, 6, 43518–43525value increase of SA1199B with noroxacin and compounds was
lower than that with noroxacin alone (Fig. 5), while the OD
value of SA1199B with compounds alone was almost the same
as SA1199B grown in isolation. The exact synergistic eﬀects on
the growth kinetics of the strain need further conrmation at
the CFU level.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineESI Fig. S5 and S6† suggested that the synergistic activity of
the compounds showed no inhibition on bacteria and no
toxicity on mammalian cells within synergistic eﬀect concen-
tration, which was encouraging and warrants further investi-
gation of the characteristics of these compounds as promising
drug hits to overcome resistance in Staphylococcus aureus.5. Conclusion
The conclusion can be drawn that these compounds may have
specic inhibitory eﬀects against the NorA eﬄux pump of strain
SA1199B, which contributes to their synergistic eﬀects with
antibiotics against this strain. Synergy may be a promising
strategy to resolve problems caused by drug-resistant strains
because the compounds with synergistic eﬀects will not cause
a reduction of bacterial growth, reducing the likelihood of the
formation of new drug-resistant mutants. Some of the classical
antibiotics could be re-introduced into a clinical role in the
therapy of infections caused by selected drug-resistant bacteria,
resulting in the use of lower doses and potentially an improved
safety prole. Furthermore, these compounds had no cytotoxic
eﬀects on the human embryonic kidney cell line (HEK293T)
within the antibacterial eﬀect concentration. This approach
may have utility against multi-drug resistant Staphylococcus
aureus.Acknowledgements
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